These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8674013)

  • 1. Pathologic staging of prostate carcinoma. What are the issues?
    Grignon DJ; Sakr WA
    Cancer; 1996 Jul; 78(2):337-40. PubMed ID: 8674013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma.
    Eichelberger LE; Cheng L
    Cancer; 2004 Jun; 100(12):2573-6. PubMed ID: 15197798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy.
    Steuber T; Erbersdobler A; Graefen M; Haese A; Huland H; Karakiewicz PI
    Cancer; 2006 Feb; 106(4):775-82. PubMed ID: 16400637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
    Han M; Walsh PC; Partin AW; Rodriguez R
    J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens.
    Epstein JI; Amin M; Boccon-Gibod L; Egevad L; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Srigley JR; Wheeler TM; Montironi R
    Scand J Urol Nephrol Suppl; 2005 May; (216):34-63. PubMed ID: 16019758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ; Partin AW; Epstein JI; Walsh PC
    Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
    Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
    Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy.
    May F; Hartung R; Breul J
    BJU Int; 2001 Nov; 88(7):702-7. PubMed ID: 11890240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?
    Roach M; Weinberg V; Sandler H; Thompson I
    Cancer; 2007 Jan; 109(2):213-20. PubMed ID: 17167758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staging of prostate cancer.
    Cheng L; Montironi R; Bostwick DG; Lopez-Beltran A; Berney DM
    Histopathology; 2012 Jan; 60(1):87-117. PubMed ID: 22212080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy.
    Kausik SJ; Blute ML; Sebo TJ; Leibovich BC; Bergstralh EJ; Slezak J; Zincke H
    Cancer; 2002 Sep; 95(6):1215-9. PubMed ID: 12216087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment.
    Vauthey JN; Ribero D; Abdalla EK; Jonas S; Bharat A; Schumacher G; Lerut J; Chapman WC; Hemming AW; Neuhaus P
    J Am Coll Surg; 2007 May; 204(5):1016-27; discussion 1027-8. PubMed ID: 17481532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
    Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
    BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence.
    Poulos CK; Koch MO; Eble JN; Daggy JK; Cheng L
    Cancer; 2004 Oct; 101(7):1563-8. PubMed ID: 15378493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.